Skip to main content
    A

    Apogee Therapeutics, Inc. Common Stock (APGE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $135.07
    +0.00 (+0.00%)

    Market Cap: $10.22B

    Last updated: Sep 04, 2026 at 5:00 PM ET

    Apogee Therapeutics, Inc. Common Stock (APGE) Financials: Revenue, Profit and Cash Flow

    Updated Aug 10, 2026. Financial statements from company filings, amounts in US dollars.

    Apogee Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$255.84M, operating cash flow was -$227.45M and free cash flow was -$232.60M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$85.85M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $285.60M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2022 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Research and development$214.71M$167.87M$68.42M$27.79M
    Operating income-$285.60M-$216.87M-$93.00M-$30.73M
    Net income-$255.84M-$182.15M-$83.98M-$39.78M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$130.00K$0$0$0$0$0
    Gross profit$0$0$400.00K$0$0$0$65.00K$0$0$0N/A$0
    Operating income-$96.00M-$82.77M-$78.06M-$71.28M-$73.17M-$63.10M-$75.88M-$58.69M-$44.12M-$38.18M-$37.16M-$24.30M
    Net income-$85.85M-$74.11M-$69.39M-$65.02M-$66.10M-$55.34M-$67.22M-$49.02M-$33.82M-$32.09M-$31.73M-$20.84M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $3.50M by $128.04M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Total assets$937.13M$753.95M$401.40M$152.06M
    Current assets$741.36M$529.71M$398.41M$152.06M
    Cash and equivalents$131.55M$141.79M$118.32M$151.89M
    Total liabilities$33.25M$37.16M$21.49M$9.98M
    Short-term debt$3.50M$3.23M$1.10MN/A
    Shareholder equity$903.88M$716.79M$379.91M-$35.39M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$1.34B$1.29B$937.13M$626.16M$657.77M$714.16M$753.95M$776.29M$800.66M$823.66M$401.40M$426.42M
    Total liabilities$141.21M$37.86M$33.25M$39.82M$38.37M$40.80M$37.16M$41.88M$27.02M$22.18M$21.49M$17.18M
    Cash and equivalents$105.57M$451.80M$131.55M$107.91M$124.19M$106.92M$141.79M$118.78M$307.30M$485.46M$118.32M$188.27M
    Shareholder equity$1.19B$1.26B$903.88M$586.34M$619.40M$673.36M$716.79M$734.40M$773.64M$801.48M$379.91M$409.24M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Operating cash flow-$227.45M-$171.17M-$74.76M-$16.43M
    Capital expenditures$5.15M$1.15M$167.00K$0
    Free cash flow-$232.60M-$172.33M-$74.93M-$16.43M
    Investing cash flow-$179.57M-$300.46M-$273.91MN/A
    Financing cash flow$396.49M$495.11M$315.39M$168.32M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$71.38M-$55.57M-$62.69M-$54.26M-$62.03M-$48.48M-$67.71M-$42.52M-$29.30M-$31.64M-$29.75M-$19.88M
    Capital expenditures$6.00K$0$62.00K$0$768.00K$4.32M$1.00K$751.00K$51.00K$351.00K$167.00K$0
    Free cash flow-$71.39M-$55.57M-$62.75M-$54.26M-$62.80M-$52.79M-$67.72M-$43.27M-$29.35M-$31.99M-$29.92M-$19.88M
    Last 12 quarters

    Frequently Asked Questions About APGE

    What is Apogee Therapeutics, Inc. Common Stock's annual revenue?

    Apogee Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Apogee Therapeutics, Inc. Common Stock profitable?

    No. Apogee Therapeutics, Inc. Common Stock reported net income of -$255.84M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does APGE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$227.45M minus capital expenditures of $5.15M produced free cash flow of -$232.60M.

    How much debt does Apogee Therapeutics, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.50M and cash and equivalents of $131.55M.